Based on individual plasma samples from 106 CHD cases occurring during the first year following randomization in the hormone therapy trials, and from 1-1 matched controls, ELISA evaluation yielded B2M concentrations that were 17.9% higher (P < 0.001) in cases versus controls (geometric mean of log-ratios of 1.179 with 95% confidence interval (CI) of 1.107 to 1.290), very similar to the 15.8% (20.212 = 1.158) higher concentration in cases compared to controls from the IPAS analyses of Table 1. Here, B2M is linked to coronary artery disorder.